ALEXANDRIA, VA–(Marketwire – October 11, 2010) – The American Diabetes Association launched its first official blog today to help put a face on a disease that kills more people each year than breast cancer and AIDS combined. The blog, called Diabetes Stops Here: Living with Diabetes; Inspired to Stop It, aims to document the Stop Diabetes® movement by reaching and engaging the 23.6 million Americans living with diabetes as well as the 57 million who are at risk for developing type 2 diabetes. 

Diabetes Stops Here will provide snap shots of the people who are committed to putting an end to this disease, from inspiring volunteer stories to moving staff experiences to celebrity stories about how to be successful while living with diabetes. The stories, interviews and news will be shared by the blog’s author, a staff member at the American Diabetes Association, who has lived with type 1 diabetes for nearly ten years. 

The Stop Diabetes movement was launched during American Diabetes Month® in November 2009 as a call to action for people to stand up against this disease and its devastating complications. The Association hopes to have one million people join the movement by the end of 2010.

“There have been so many touching moments in the movement to Stop Diabetes since we launched last year,” commented Larry Hausner, CEO, American Diabetes Association. “People have shared courageous stories of facing their diabetes head on, while others have shared their heart-breaking experiences of losing a loved one because of diabetes. The blog is a new way to raise our collective voices and tell people why we need to Stop Diabetes once and for all.” 

Some of the most vocal diabetes stories come from blogs and other social media platforms which create a broad online community of people who have diabetes or whose loved ones are living with the disease. “By means of this blog,” noted Hausner, “we hope to add our voice to this dialogue and further engage with those who may be well aware of the effects diabetes can have on their lives.”

Today’s first post is titled “Why ‘Stop Diabetes’?” can be found at www.diabetesstopshere.org. This initial post seeks to explain why the Stop Diabetes movement was created and its goal for engaging the public. “The goal of the Stop Diabetes movement is to grow to epic proportions, to be bigger than the disease itself,” the blog explains. “In short, it’s the answer to why the Association does the work that it does.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

COLUMBIA, SC–(Marketwire – October 11, 2010) – BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced the continuing expansion of the company’s specialty pharmaceutical portfolio with the launch of a new Animal Health Division, 4legPharma. This latest BDI Pharma expansion, focused on the biopharmaceutical needs of the veterinary specialist, is supported by the launch of its own website, www.4legpharma.com, as well as a staff of highly trained representatives dedicated to service this unique marketplace.

“As the Animal Health Division of BDI Pharma, 4legPharma is backed by over 15 years of experience in handling urgent need, critical care pharmaceutical products. We are uniquely positioned to offer veterinary specialists the best of both animal drugs as well as human therapies for extralabel use to treat pets suffering from the same chronic, life-threatening conditions that affect humans. Our customers appreciate that we deliver the safety of a secure product distribution channel and a level of personal service that is unrivaled in the veterinary medical community,” said Angela Phillips, Director of Animal Health.

The US Bureau of Labor Statistics states that the number of veterinary jobs is expected to increase thirty-three percent (33%) by 2018 as a whole, and reports published by the AVMA indicate an average annual increase of eleven percent (11%) in the number of veterinarians seeking board-certification to specialize in the areas of internal medicine, anesthesiology, dermatology, and seventeen other recognized specialties.

“At BDI Pharma, it is our commitment to bring definable value and uncompromising service to our customers and trade partners that sets us apart from others,” stated Edward Stiefel, Jr., Co-President of BDI Pharma. “Our Animal Health Division is a testament to the capabilities and resources we are willing to dedicate to service the specific nature of a growing marketplace.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation’s healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, www.bdipharma.com has become an industry renowned point of reference. Proprietary programs for product consignment (www.consignadvantage.com), flu vaccine pre-booking (www.securiflu.com), vaccine ordering (www.securivax.com) and purchasing/reward programs (www.qoreprogram.com and www.securigam.com) round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.

DALLAS, TX–(Marketwire – October 11, 2010) –  JC Data Solutions (PINKSHEETS: JCDS), a provider of innovative and cost-effective solutions for digital office workflow and data management focusing on the Oil & Gas, Legal and Healthcare industries, has entered into an agreement to provide their Payment Manager™ services to Legacy Reserves, LP of Midland, TX.

The Payment Manager™ software, designed by JCDS especially for the Oil & Gas Industry, is part of a turnkey service that automates the distribution, delivery and archival of payments and documents to payees through ACH/EFT and posts documents to the web. The service also offers printing checks and/or statements, joint interest billing and other cost-effective data management functions.

Legacy, a public company traded on the NASDAQ under symbol LGCY, is an independent oil and natural gas limited partnership headquartered in Midland, Texas, specializes in Oil & Natural Gas Operations in the Permian Basin and Mid-Continent Regions focusing on the acquisition and development of oil and natural gas properties.

Cary Allen, CEO of JCDS, said, “Legacy Reserves is growing and recognized the need to streamline some of their processes. Payment Manger™ provides several key operational advantages as well as significant reduction of paper and manpower associated with their distribution process.”

Forward-Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are “forward-looking statements” are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as: the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels.

All information in this release is as of the date of this release.

MONMOUTH JUNCTION, NJ–(Marketwire – October 11, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, was chosen to present at the AdvaMed 2010 MedTech Conference at the Walter E. Washington Convention Center in Washington, D.C. next week. Dr. Phillip Chan, Chief Executive Officer, will speak Wednesday, October 20, 2010 at 10:10AM EDT in Room 204a.

http://www.advamed2010.com/go.cfm?do=Page.View&pid=80

Following the meeting, the presentation will be made available on the company’s investor relations website: http://www.cytosorbents.com/invest.htm

About AdvaMed 2010

AdvaMed 2010 is the premier MedTech conference for business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world. In only its third year, AdvaMed 2009 attracted 1,400 industry leaders — including 500+ CEOs, Presidents and C-level executives. For more information, visit www.AdvaMed2010.com.

About CytoSorbents and CytoSorb™

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, often called “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial — a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and other. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

LOS ANGELES, CA–(Marketwire – October 8, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (the “Company”) today announced that David A. Boyden, a member of MMRGlobal’s Board of Directors (the “Board”) since January 2009, has notified the Company of his intent to resign from the Board, effective today. There were no disagreements between the Company and Mr. Boyden which led to his decision to resign.

“Dave joined the Board at the request of the pre-merger Faville, Inc. Board of Directors and has contributed to the Company’s efforts in the exploitation of its biotech assets. He is not resigning due to disagreements with the Company or its officers over operations, policies or practices,” said Robert H. Lorsch, MMRGlobal Chairman and CEO. “We appreciate Dave’s many contributions to the Company since the merger and I will miss his involvement. The Company plans on a search for a replacement director with expertise in biotech, insurance or banking.”

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

DENVER, CO and PHOENIX, AZ–(Marketwire – October 8, 2010) –  The Amergence Group (PINKSHEETS: AMNG), a company that focuses on developing, nurturing, and rapidly expanding selected emerging or “disruptive” companies across a wide range of industries and disciplines, announced today that it has completed the successful acquisition of Altitude Organic Licensing Corporation (AO) which is headquartered in Denver, Colorado. Terms for the acquisition will be disclosed in a subsequent release.

The company currently has 5 stores using its Altitude Organic™ Trademark who pay an annual license fee of $15,000 per year. Banding together for strength, the Altitude Organic licensee-dispensaries receive joint-marketing benefits, limited free marketing from corporate, purchasing power on all approved partner products and services, national brand recognition, lobbying efforts, medical marijuana consulting, commercial real estate placement and attorney advisory in addition to booth space at the annual convention.

AO’s prez, Brian Cook, said, “Thanks to the Amergence Group we will now be able to offer a stock compensation plan for all our store owners. I believe this will be a tremendous incentive for prospective dispensary licensees. In addition, our ownership of the National Medical Marijuana Association (NMMA) will put Altitude Organic in ‘pole position’ to provide the best services to our licensees and their customers and enable Altitude Organic to capitalize on this exploding trend. Through this growth process, we must always remain vigilant to defend our high quality standards, developing protocols, and compassionate customer service for our patients.”

Amergence managing director Peter Jacobs stated, “Our acquisition of Altitude Organic Licensing Corp. at this time makes perfect sense for Amergence shareholders. I have been seeing this ‘marijuana legalization wave’ building since 1970 and I sense it is getting ready to crest. The Company’s timing for this acquisition couldn’t be better.”

Altitude Organic Medicine medical marijuana centers are currently located in Denver, CO, Colorado Springs, CO, and San Diego, CA.

The National Medical Marijuana Association (NMMA) commercial can be viewed here: http://www.youtube.com/watch?v=hXQMsPlKJcc

To learn more about the National Medical Marijuana Association visit them here: http://nationalmedicalmarijuanaassociation.org/ 

ABOUT THE AMERGENCE GROUP
The Amergence Group’s (PINKSHEETS: AMNG) provides valuable advice and support to new businesses with its goal of accelerating their intended plans to introduce edgy, disruptive, and/or innovative technologies to the world market. The Company’s 8-year-old Tranzbyte division continues to focus on the development and marketing of its innovative group of optical media enhancement technologies worldwide such as FLASHAlbum, a technology which enables distributors of optic disc media (CDs and DVDs) to combine the best features of both on one USB flash drive.

ABOUT ALTITUDE ORGANIC LICENSING CORPORATION
Altitude Organic Licensing Corporation was founded in Denver during the medical marijuana industry “fever” of early 2010. AO Licensing Corp. generates revenue in the fastest growing industry in the United States without carrying the liability of growing and selling marijuana. The company generates revenue by licensing its “Altitude Organic^™” Federal Trademark to dispensaries. The company also offers medical cannabis advocacy and consulting services to its licensed dispensaries. The corporate website can be found at: www.AltitudeOrganicMedicine.com.

NOTES ABOUT FORWARD-LOOKING STATEMENTS

Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

FLEMINGTON, NJ–(Marketwire – October 8, 2010) –  Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today that another of the required SEC documents to bring the company current was submitted today for EDGAR review. The first quarter 2009 Form 10-Q has been completed and submitted to Marketwire for conversion and filing with the U.S. Securities Exchange Commission. This filing will be completed by Marketwire. Additional filings will be made over the next two weeks. The annual report for 2008 (end of year 10-K) will be submitted by the end of next week, as it is still under final attorney review; Second quarter 2009 Form 10Q will be filed within the next week. The company will continue to step up its effort to bring the company current as a pink sheet company as quickly as possible.

Information set forth in this press release contains various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the “Act”) provides certain “safe harbor” provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management’s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “should,” “will,” and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. 

SAN DIEGO, CA–(Marketwire – October 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today it has entered into a commercialization agreement with the Indianapolis-based company, General Biotechnology LLC (http://www.gnrlbiotech.com), for sale of its universal donor Endometrial Regenerative Cells (ERC) as a research reagent to qualified academic and corporate institutions. Under the agreement General Biotechnology will harvest menstrual blood from qualified donors, isolate research-grade ERC stem cells, expand and qualify said stem cells and provide a distribution mechanism through its sales network.

“Medistem is a unique company in the area of cellular therapeutics in that its universal donor stem cells have already been used to treat humans,” said Dr. Erik Woods, President and CEO of General Biotechnology LLC. “By making these cells commercially available, scientists around the world will have the ability to compare these cells to existing adult stem cells such as placental, cord blood, and adipose mesenchymal stem cells.”

To date Medistem has reported the use of ERC in treatment of patients with Multiple Sclerosis http://www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf, Duchenne Muscular Dystrophy http://www.ncbi.nlm.nih.gov/pubmed/19917503, and Heart Failure http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

“Since we originally reported the discovery of Endometrial Regenerative Cells in 2007, at least 4 independent groups have used and published on cells with identical or near-identical properties to treat animals with diabetes, Parkinson’s, stroke, and heart failure,” said Dr. Vladimir Bogin, Chairman and President of Medistem. “Given our intellectual property position on these cells, we are confident that by increasing their use in the scientific community we will accelerate our own development efforts, as well as advance the field forward.”

Dr. Michael Murphy, a Harvard-trained vascular surgeon who performs clinical trials using adult stem cells at Indiana University, stated, “The ERC stem cell population represents a treatment for vascular diseases that is novel, highly potent, and easy to integrate into the current standard of care. I am eager to initiate clinical investigations with these cells in treatment of critical limb ischemia.”

Dr. Murphy is the Principle Investigator for an IND filed with the FDA for treatment of critical limb ischemia with Medistem’s ERC stem cells.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

EVERETT, WA–(Marketwire – October 7, 2010) –  Fluke Corporation, the global leader in portable electronic test and measurement technology, will send a lucky professional and companion to Arlington, Texas for football’s “Big Game,” simply for learning about the innovative new tools Fluke has recently introduced.

The winner of the Fluke football BIG GAME SWEEPS will receive two tickets to attend the biggest bowl game in football come February 6, 2011. The sweepstakes package includes airfare, three nights of lodging, and a complimentary rental car. The winner will be selected by random drawing and announced the first week of January 2011.

The Fluke football BIG GAME SWEEPS marks the start of an exciting season for Fluke customers. Fluke has just announced a new family of innovative, high-performance clamp meters. Other recent introductions include the groundbreaking Fluke 233 Remote Display Multimeter, the first of its kind in the industry; the Fluke 28 II Industrial Multimeter for ultra rugged conditions; and the Fluke Ti32 Thermal Imager with a powerful 320 x 240 sensor. 

To enter the Fluke football BIG GAME SWEEPS, customers simply choose a featured product online at www.fluke.com/footballsweeps, read a short description and then complete a registration form for a chance to win. Contestants are limited to one entry per person. No purchase is required.

Participation in the Fluke football BIG GAME SWEEPS is limited to licensed contractors or individuals in a professional trade who are residents of the U.S. and age 21 or older.

Sweepstakes ends December 31, 2010. See official rules at www.Fluke.com/footballsweeps.

For More Information

Fluke test instruments are distributed in more than 100 countries. For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail [email protected] or visit the Fluke Web site at http://www.fluke.com.

Follow Fluke on Facebook, Twitter, YouTube or Linkedin.

About Fluke

Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools. Fluke tools deliver the testing and troubleshooting capabilities that are critical to keep commerce and industry running smoothly. Fluke customers are technicians, engineers, electricians, metrologists and building diagnostic professionals who install, troubleshoot and manage industrial, electrical and electronic equipment and calibration processes for quality control and building restoration. In the past five years, Fluke tools won more than 50 industry awards, including Test and Measurement World Best in Test, Control Engineering Engineer’s Choice, and Plant Engineering Product of the Year. Fluke is a registered trademark of Fluke Corporation in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

EVERETT, WA–(Marketwire – October 7, 2010) – Fluke Corporation, the global leader in portable electronic test and measurement technology, has introduced new iFlex^™ flexible current probes, designed to make current measurement easier, more convenient and more precise for electricians and industrial technicians.

The new Fluke iFlex flexible current probes expand the measurement range of select Fluke meters to 2500 A ac and give technicians the ultimate in measurement flexibility. The large coil allows users to reach around large or awkward-shaped conductors up to 6 inches in diameter, while the small 0.3-inch profile allows the coil to reach between tightly-packed cables and improves access in crowded spaces. A 6-foot cord makes it easier to see readings at a distance from the conductor.

The iFlex probes connect directly to the meter, displaying current measurements without error-prone scaling factors. In addition to ac current measurement, they also work with frequency, inrush, and min/max/avg functions. The iFlex current probes are available in 10-inch and 18-inch sizes.

The iFlex current probe i2500-18 is included with the new Fluke 381 and Fluke 376 Clamp Meters. Both iFlex models — the i2500-18 and the i2500-10 — are compatible with Fluke 374 and Fluke 375 Clamp Meters. US list price for each iFlex probe model is $98.95.

The iFlex current probes are members of a new family of Fluke clamp meters designed to meet users’ requirements for flexibility, safety and performance in the most challenging industrial conditions. This new Fluke family of clamp meters includes:

Fluke 381 Remote Display True-rms AC/DC Clamp Meter with iFlex — The Fluke 381 is a full-featured clamp meter with an important extra: Users can remove the detachable wireless display for even more flexibility, convenience and safety. Now one technician can do jobs that used to require two. US list price is $498.95.

Fluke 376 True-rms AC/DC Clamp Meter with iFlex — With the new Fluke 376 Clamp Meter, users will be ready for any measurement challenge. Designed for the toughest industrial environments, it measures current up to 2500 A ac and 1000 A dc and can troubleshoot even the noisiest motors and drives. US list price is $374.95.

Fluke 374 and 375 True-rms AC/DC Clamp Meters — The new Fluke 374 and 375 clamp meters offer improved performance, perfect for many current measurement situations. With true-rms ac voltage and current measurements, the Fluke 374 and 375 can read up to 600 V and 600 A in both ac and dc modes and handle min/max, average and inrush recording. Both are compatible with the new iFlex flexible current probe (sold separately). US list price for the Fluke 375 is $299.95, for the Fluke 374, $259.95.

Fluke 373 True-rms AC Clamp Meter — The new Fluke 373 clamp meter offers improved performance and maximum value for users requiring ac only current measurement. US list price is $179.95.

The Fluke 381, 376, 375, 374 and iFlex current probes are rated for safe use in hazard category IV (CAT IV) 600V environments (CAT IV 600V, CAT III 1000 V) as defined by safety regulators in the US, Canada and Europe. The Fluke 373 is rated CAT IV 300V, CAT III 600V. Category IV environments include overhead power lines, underground power lines and service entrance power, as well as all outdoor environments.

For More Information

Fluke test instruments are distributed in more than 100 countries. For more information on the entire new Fluke clamp line, go to www.fluke.com/ReadyForAnything. For more information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail [email protected] or visit the Fluke Web site at http://www.fluke.com.

Follow Fluke on Facebook, Twitter, YouTube or Linkedin.

About Fluke

Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools. Fluke tools deliver the testing and troubleshooting capabilities that are critical to keep commerce and industry running smoothly. Fluke customers are technicians, engineers, electricians, metrologists and building diagnostic professionals who install, troubleshoot and manage industrial, electrical and electronic equipment and calibration processes for quality control and building restoration. In the past five years, Fluke tools won more than 50 industry awards, including Test and Measurement World Best in Test, Control Engineering Engineer’s Choice and Plant Engineering Product of the Year. Fluke is a registered trademark of Fluke Corporation in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

CHARLOTTE, NC–(Marketwire – October 6, 2010) – Patient Care Technology Systems (PCTS), a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR) today announced they have signed a record number of contracts for the year and that 100% of their existing tracking customers have renewed their agreements for ongoing solutions and services.

“There is no stronger endorsement of our company and solutions than the dramatic increase in new contract signings and the continual renewal, and expansion of customer agreements. Every year, our customers almost unanimously renew their agreements. They expand their implementations while finding greater value in our breadth of solutions,” said Tony Marsico, PCTS president and CEO.

Renewals are executed when customers want to extend their agreement with PCTS to provide additional products, maintenance and/or support. So, the 100% renewal rate means that every customer who was with PCTS in January of 2010 will continue their agreements in 2011.

“The renewal of these agreements is extremely important as they not only provide a viable, ongoing stream of revenue that supports enhanced research and development, but also because they provide validation that the company as a whole is approaching the market with the right innovative solutions that are clearly in demand. The benefits of these solutions more than justify the investment the health care organizations are making in PCTS. The financial and performance advantages we offer our clients are what’s driving the accelerating growth we are seeing,” says Warren Mosler, CEO of Consulier Engineering, the primary shareholder of PCTS.

“What is equally exciting, is that almost every customer doesn’t just renew their existing agreement, but actually comes back to us for additional work each year,” states Jaime Ojeda, PCTS vice president of sales and business development. Ojeda says, “In 2010 alone, we will have about 70% of our existing tracking customers expand their PCTS installations. This, combined with the record number of sales we have made to new customers, is what is driving our continued growth and validates PCTS as the ‘go to’ provider of healthcare real time locating and workflow automation systems. PCTS has been supporting the healthcare industry since 1997 and our exceptional growth will allow us to expand our offerings.”

To facilitate and manage this growth, so far in 2010, PCTS has increased employment by almost 20% and is estimating almost double that in 2011.

“That we have been able to increase revenues as much as we have with only a 20% increase in staff is also very encouraging,” says Tony Marsico. “The work we have done to deliver our solutions in as efficient a way as possible is allowing us to enjoy the tremendous growth without excessive increases in overhead or any need to increase prices.”

In February of this year, the company announced the opening of a subsidiary based outside of London that will service the UK and European Union. Patient Care Technology Systems, Ltd. is holding two seminars the week of October 11 that will present innovative techniques for improving accident and emergency department (A&E) productivity, streamlining workflow, and improving overall operational efficiency and quality of practice.

Tony Marsico adds, “Since becoming CEO in April 2005, my emphasis, and hence our company’s emphasis, has been ensuring that our customers realize the complete value of our solutions. This includes much more than just customer service. We are automating hospital workflow through visibility, communication and real-time tracking of interactions between entities, patients and staff. This has successfully allowed our customers to consistently enhance revenue and contain costs, resulting in solid, bottom-line returns on their investment. Our renewal rate shows that they are getting that ROI and our focus is paying off.”

About Patient Care Technology Systems

Patient Care Technology Systems, a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR), helps health care providers to improve patient flow, increase capacity and improve patient and staff safety by visualizing the real time location and status of people and equipment throughout their facility. PCTS solutions have supported over 2 million patient visits annually and have shown a proven return on investment in high turnover, high-acuity units such as the emergency department and perioperative suites. The Amelior Enterprise Visibility and Workflow Automation Suite™ is interoperable with all leading locating technologies, including active-RFID, infrared, ultrasound, ultra-wideband, Wi-Fi and ZigBee. PCTS customers have been recognized nationally for improvements in efficiency and clinical excellence. For more information, visit www.pcts.com and connect to PCTS on Facebook and Twitter.

This press release contains forward-looking statements within the meaning of federal securities laws. PCTS and CSLR caution you that any statements contained in this press release which are not strictly historical statements constitute forward-looking statements. Such forward-looking statements include, but are not limited to, those related to PCTS’s and CSLR’s expectations regarding continued business growth. These statements are neither promises nor guarantees, and involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, (copies of which may be obtained at the SEC’s website at: http://www.sec.gov) — could impact the forward-looking statements contained in this press release. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. PCTS and CSLR disclaim any obligation to publicly update or revise any such statements to reflect any change in PCTS and CSLR’s expectations, or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Click here to see all recent news from this company

VICTORIA, BRITISH COLUMBIA–(Marketwire – Oct. 6, 2010) – Vigil Health Solutions Inc. (“Vigil”) (TSX VENTURE:VGL) is pleased to announce its selection as one of the fastest-growing companies in B.C. by Business In Vancouver newspaper. Vigil, and other award recipients, were honoured at the Top 100 Fastest Growing Companies reception held last night in Vancouver. Vigil was ranked 40th among 100 of the fastest growing companies in B.C. based on revenue growth for the five-year period between fiscal 2005 and 2009.

About Vigil Health Solutions Inc.

Vigil offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding seniors’ housing market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System™ (Vigil® System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity.

PHILADELPHIA, PA–(Marketwire – October 6, 2010) –  There is much focus on patient recruitment, specifically finding patients willing to participate in clinical trials. However, the second phase of recruitment is often overlooked: pulling prospective patients through the referral pipeline and into the study center. This phase occurs after patients pass a pre-screener that matches them to the study’s criteria. It is during this phase that pre-screened patients wait for site follow-up that often does not occur.

To streamline the recruitment ‘pull-through’ process and increase recruitment success, MediciGlobal introduces the Study Resource Center™ and welcomes Pat Patterson, RN, CCRC as its Director. Pat is a certified clinical research nurse with nearly 20 years of clinical research experience at academic, hospital and community based research settings. Pat has seen first-hand the need for a central resource providing sites with services that save time on processing patient referrals.

MediciGlobal established the Study Resource Center in response to growing numbers of requests from study coordinators and site marketing managers to directly provide services that support finding patients, pulling those patients most likely to randomize through the referral pipeline, and retaining patients long term.

The Study Resource Center is a place for sites to go when they need recruitment-retention support. Pat contends that study coordinators like to know they are dealing with someone who understands their issues. MediciGlobal has supported sites indirectly through study sponsors, but now these services can be accessed directly by sites, and include:

1. Education: building effective recruitment-retention programs
2. Efficient pre-screening
3. Logistical support: appointment scheduling, patient follow up
4. Problem solving: innovative recruitment approaches. 
5. Advertising and eMarketing support
6. Retention: during and post active treatment
7. Lost-to-follow up: Find missing patients

The Study Resource Center integrates MediciGlobal’s Site Support team with the services of its in-house patient contact center, ProtoCall^®. Centralizing these functions enhances the coordination of critical recruitment-retention support services to study sites.

Ms. Patterson was one of the first to undergo the Association of Clinical Research Professionals’ (ACRP’s) qualification process for a certified clinical research coordinator (CCRC). Recognized as a consistent performer for studies conducted for major biopharmaceutical sponsors, Pat served on numerous national and international study advisory boards.

About MediciGlobal
MediciGlobal based in the U.S. and U.K., is a specialty patient recruitment — retention company, developing programs for clinical trials of all sizes in countries around the globe. www.mediciglobal.com

DUBAI, UNITED ARAB EMIRATES–(Marketwire – Oct. 6, 2010) – The recent re-launch of a global networking web-site has attracted thousands of healthcare industry affiliated professionals keen to share information on-line. The website, www.GlobalHealthcareNetwork.com was revamped last month to help facilitate (showcase/broadcast) research, provide business & networking opportunities and act as an easily accessible forum for healthcare issues and challenges (around the world to be discussed) The site is also proving popular as an informal tool that allows members to socialise with their healthcare peers in other countries.

“This is the age of social networking and a great deal of information is now being traded (exchanged) on-line using this method,” said Dr. Prem Jagyasi, renowned global healthcare consultant and founder of the Global Healthcare Network. “There are many general purpose social networking sites with millions of users, but we were encouraged by healthcare professionals across the world to create a site designed especially with the sector in mind,” he added.

The www.GlobalHealthcareNetwork.com is unique in that it has customised settings so that healthcare professionals can participate in specific activities. Healthcare professionals using the site can join various special interest groups in the sector; such as Healthcare Management, Healthcare Marketing, Healthcare Insurance, Pharmaceutical, Medical Equipment, Healthcare Finance, Healthcare Journalist and, Medical Tourism (Health Tourism / Healthcare Travel / Medical Travel), amongst others.

The site also aggregates the latest news from around the world to provide easy access of vital healthcare information at one place, as well as offering all the standard networking benefits that include connections, blogging, forum discussions, media uploads and event updates. The network is integrated with Facebook and Twitter so members can post to other networking sites from Global Healthcare Network. The Global Healthcare Network also has group/fan pages on LinkedIn, Facebook and Twitter, with more than 1750 members actively communicating.

Dr. Jagyasi believes that the advantage of the Global Healthcare Network is that it allows for health professionals to share information easily, which in turn breaks down barriers and improves cooperation between healthcare providers. “Even the small links that are established through purely social interaction can develop into bigger links over time, as channels of communication become progressively embedded,” he said. “We can see from the buzz and chatter happening on the site that connections are being made that should lead to the forging of relationships that can only benefit healthcare in the future. I believe that this site will act as an important adjunct to the continued growth of the sector worldwide,” he added. 

The site provides us with updated information about all upcoming healthcare events worldwide at one place.

Dr Prem Jagyasi, recently presented the topic ‘ Social Media Marketing’ at the World Medical Tourism and Global Healthcare Association 2010 in Los Angeles, USA. The presentation provided a prescriptive roadmap for Online Media and Social Media Success while discussing best practices and answering the biggest questions faced by health care marketers in the field of Social Media Marketing. His presentation is also available to view on www.slideshare.net/jagprem or www.GlobalHealthcareNetwork.com or www.DrPrem.com.

Anyone, health professional or otherwise, can access the Global Healthcare Network by logging on to http://www.globalhealthcarenetwork.com and creating a user account. They will then be able to connect to health workers from around the world.

Below are quick links:

Global Healthcare Network Site: www.GlobalHealthcareNetwork.com

Members: http://www.globalhealthcarenetwork.com/profiles/members/

Notes & News http://www.globalhealthcarenetwork.com/notes/index/allNotes

Forums http://www.globalhealthcarenetwork.com/forum

Blogs http://www.globalhealthcarenetwork.com/profiles/blog/list

Facebook Page http://www.facebook.com/pages/Global-Healthcare-Medical-Tourism-Health-Tourism/105868006128124

LinkedIn http://www.linkedin.com/groups?mostPopular=&gid=2997546

Twitter http://twitter.com/Globalhcn

About Global Healthcare Network

Global Healthcare Network is a unique social networking platform for Healthcare Professionals. Join the group now to Network, share & learn. There is a total of 1750+ Network members across all Global Healthcare Networking sites/pages including facebook & linkedin.

The network allows you to create blog, start discussion, join various healthcare groups, promote your services.

About Dr Prem Jagyasi

A successful entrepreneur and experienced strategic professional, Dr Prem Jagyasi is a renowned Chartered Management, Healthcare Marketing and Medical Tourism Consultant. Providing high-profile consultancy services to Government authorities and private healthcare organizations, Dr. Prem Jagyasi is a noticeably leading Global Healthcare and medical tourism consultant in the world.

Apart from running a successful healthcare solution firm and consultancy business, he has initiated several innovative healthcare awareness projects such as Family Health Festival, No Tobacco Campaign, Summer Health Festival, Ahlan Ramadan and Diabetes Events. His initiatives are endorsed and recognized by the country’s ministry of health and other government authorities. On a global front, he is also working on Medical Tourism Guide, Educational Events, Global Health Directory, and workshops on quality practice for international patients. etc.

Currently, Dr Prem Jagyasi is MD & CEO of ExHealth, a Dubai HealthCare City based firm engaged in offering multi-dimensional healthcare solutions in international domain. He also serves the Medical Tourism Association (also known as Global Healthcare Association) —a Non Profit organization based in USA as Honorary Chief Strategy Officer. He is also the Chief Editor of UAE’s leading health magazine – HealthFirst, published in association with one of the leading English dailies of the region.

LOS ANGELES, CA–(Marketwire – October 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today that its MMR Stimulus Program will be expanded to include the MMRPro Insurance Advance Program. This program is an expansion of the existing MMRPro Stimulus Program launched in the first quarter of 2010 which rewards MMRPro users when their patients upgrade to the MyMedicalRecords Personal Health Record. 

The Insurance Advance Program is designed to help MMRPro healthcare professionals smooth out cash flow during their transition to achieving meaningful use. MMRPro users will be paid advances on the uncollected commercial third-party amounts they billed each preceding week to the extent permitted by federal and state laws and regulations. They must use an MMRGlobal approved Stage 1-Certified Meaningful Use practice management and billing system to be eligible to receive payments under the MMRPro Stimulus Insurance Advance Program. The program will be part of the Company’s previously announced plans to offer one or more EMR products, which could include applications for iPad and PC-based platforms in addition to its MMRPro and MyMedicalRecords Personal Health Record products. 

“We recognize that converting an existing billing system to one that enables the practice to achieve meaningful use could affect a practice’s cash flow, which could also affect the lifeblood of the practice,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “One of the largest problems doctors and hospitals face today is reimbursement for their services. Our goal is to assist doctors, hospitals and medical groups in maintaining control of their finances while transitioning to meaningful use at the same time healthcare reform is being implemented.”

Additionally, MMRPro users and their patients continue to receive protection under MMRGlobal’s million dollar Cyber Liability Insurance Policy, which, among other things, protects healthcare professionals using MMRPro defend themselves in the event of a violation of the expanded HIPAA regulations under the Health Information Technology for Economic and Clinical Health Act (HITECH). 

The underlying Cyber Liability policy is underwritten by an A-rated insurance company by A.M. Best to cover damages arising from the use and deployment of the Company’s personal and professional health record products and services. The coverage extends to MMRGlobal’s corporate clients that offer MMR’s products and services as an employee benefit and to individuals who sign up to receive MMR’s services over the Internet.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “help,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products and programs are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; variations in our quarterly operating results; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product and program introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – October 6, 2010) – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for the Company’s PD2i Analyzer™ and PD2i CA™ (Cardiac Analyzer). According to the terms of the agreement, Dell will create Vicor-labeled laptop computers specifically customized to Vicor’s specifications and package them for Vicor’s worldwide distribution. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

 “We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater. 

“Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as Dell and the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to successfully complete the normal range study for PD2i^®values; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-18

Click here to see all recent news from this company

KANKAKEE, IL–(Marketwire – October 5, 2010) – Riverside Medical Center has now joined the Illinois Hospital Association’s (IHA) “Raising the Bar” initiative to continue improving the level of quality of South Chicago Illinois healthcare and patient safety. Two hundred hospitals including Riverside are participating in the “Raising the Bar” initiative to make Illinois a national leader in healthcare. 

Riverside leaders pledged to share best practices through the IHA Quality Care Institute. The pledge includes implementing innovative methods to prevent and reduce infections and other complications leading to unnecessary hospital re-admissions. Riverside signed the Raising the Bar: A Call to Action pledge, proving this Kankakee County hospital is dedicated to patient safety and success.

Phil Kambic, President and CEO of Riverside, stated, “Our signature on the pledge is further evidence of Riverside’s everyday mission to provide remarkable, quality healthcare experience to every one of our patients and their families. Riverside is continually recognized as a leader in patient care and safety. And the standards we subscribe to make that possible.”

Over the next three years, Illinois hospitals will be “Raising the Bar” on current standards. Hospitals joining the pledge must reduce re-admissions and infections acquired in hospitals along with other complications. Riverside and other Illinois hospitals are “Raising the Bar” to develop and implement key programs to achieve these goals. 

The “Raising the Bar” initiative seeks to help hospitals improve quality in major areas such as lowering 30-day hospital readmission rates for pneumonia, heart attack and congestive heart failure and minimizing infections and conditions acquired in hospitals such as surgical-site infections, C. difficile, Methicillin-resistant Staphylococcus aureus (MRSA), catheter-associated urinary tract infections (CAUTI), central-line associated bloodstream infections and pulmonary embolism and deep vein thrombosis following select orthopedic procedures.

By working through IHA’s Quality Care Institute, Riverside has access to tools, best practices and essential data from across the state as well as from state and national experts. These facilities help the Southern Chicago suburbs hospital offer better quality and improve patient safety through developing practical approaches for improving patient care and active advocacy to coordinate care.

To find out more about how Riverside Medical Center is “Raising the Bar,” visit www.RiversideMC.net. To learn more about IHA and the Quality Care Institute, visit www.illinoishospitals.org.

Click here to see all recent news from this company

WASHINGTON, DC–(Marketwire – October 5, 2010) –  Did you know that birth defects occur in 7 out of every 10,000 live births in the U.S.? And Spina Bifida is the most common permanently disabling birth defect? In honor of October being Spina Bifida Awareness Month, the Spina Bifida Association is asking folks to take a few minutes today and get involved in the awareness month by educating loved ones.

The first question many have: What exactly is Spina Bifida? In short, Spina Bifida happens when the spinal column doesn’t close completely.

And how many births each day are affected? Well, it’s hard to believe, but eight births each day are affected by Spina Bifida or a similar birth defect of the brain and spine. If you think about it, there are currently over 65 million women in the U.S. who could become pregnant and each one of these ladies is at risk of having a baby born with Spina Bifida. So because Spina Bifida occurs during the first month of pregnancy (that’s even before most women know they’re pregnant!) it is that much more important to take proper precautions to help try to prevent it now. 

Okay. So what type of precautions can help in prevention, you may wonder?  
Although at this time there is no known cause of Spina Bifida, research has shown that if a woman takes 400 mcg of folic acid every day and before she becomes pregnant, she reduces her risk of having a baby with Spina Bifida or another neural tube defect by as much as 70%! That fact is reason enough to encourage women (and men) to get out there this month and spread awareness.

Families with a history of Spina Bifida should take extra dosages of folic acid prior to pregnancy. Hear one mom’s message: http://www.youtube.com/watch?v=qshRfegnGD4

And in honor of October’s Spina Bifida Awareness Month, SBA will also be launching some great new online resources, including:

1. SB University (SBU) (www.sbuniversity.org), a new online educational program featuring taped sessions from the 2010 National Conference as well as monthly live seminars conducted by Spina Bifida medical professionals from around the country. During Awareness Month, SBU will debut new sessions each Monday.

2. SBTween2Teen (www.sbtween2teen.org) a new Web site for tweens and teens with Spina Bifida. Complete with blogs, videos, real stories, fact sheets, and an Ask the Expert feature, the interactive site helps tweens and teens navigate the difficult road to adulthood. There is even a social networking component run through Facebook, allowing tweens and teens to interact with one another and build peer-to-peer relationships!

3. Preparations, a new transition-focused Web site launching in late October allowing parents, caregivers, and clinicians to answer specific questions with regard to a child’s developmental milestones. This tool can even help young adults remedy some transitional challenges.

For even more information, tips and resource, you may visit: www.spinabifidaassociation.org
And be sure to join the Spina Bifida Association on Facebook: www.facebook.com/spina.bifida.learn

The Spina Bifida Association (SBA) serves adults and children who live with the challenges of Spina Bifida. Since 1973, SBA has been the only national voluntary health agency solely dedicated to enhancing the lives of those with Spina Bifida and those whose lives are touched by this challenging birth defect. Its tools are education, advocacy, research, and service. Through its network of chapters, SBA has a presence in more than 125 communities nationwide and touches thousands of people each year. For more information visit: www.spinabifidaassociation.org.

id=”nav_links”>

MIAMI, FL–(Marketwire – October 5, 2010) –  CareCloud, a provider of on-demand software and services for the healthcare industry, today announced it has closed a $5 million round of investment capital. Investors include a cadre of prominent entrepreneurs and business leaders. The Company has raised in excess of $7.8 million to date.

“We are delighted with the outpouring of support from our investors. They share our passion and vision to revolutionize the healthcare experience with our digital ecosystem,” said CareCloud President and CEO, Albert Santalo. “This funding is validation of the tremendous progress the company has made since closing its first round in January of 2010. We are experiencing explosive growth since our product launch in March of 2010, and we plan to use this capital to invest in our software development and service infrastructure while fueling additional growth.”

CareCloud offers a suite of web-based apps that allow physicians to manage their business and also allows them and their patients to communicate and collaborate with each other in real time across multiple points of care via the company’s web-based digital ecosystem. By leveraging the power of cloud computing to deliver technology-enabled services to healthcare providers, CareCloud is creating an integrated environment where all participants share a common commitment to reducing inefficiency and providing excellence in care.

CareCloud received global attention recently for winning top honors at IBM’s SmartCamp competition, an exclusive mentoring program through which IBM seeks to identify and support innovative new technology companies. As the winner of the Silicon Valley SmartCamp event, CareCloud will be competing against other winners from around the globe for the title of “World’s Smartest Startup,” as well as for the attention of many of the world’s most prominent venture capitalists.

About CareCloud
CareCloud is a web-based software and services company that modernizes the workflow in a medical practice. Visit CareCloud online at www.carecloud.com, blog.carecloud.com, or www.twitter.com/carecloud.

Click here to see all recent news from this company

OXFORD, UK–(Marketwire – October 5, 2010) –

Mirada Medical Limited
(“Mirada” or “the Company”)

Mirada Medical Announces the Release of its Advanced XD3 PET-CT and Fusion Package on Sectra PACS

Oxford, UK and Pennsylvania, US, 5 October 2010: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that its latest XD3 multi-modality image fusion analysis package is now available as an option to users of Sectra PACS. 

The latest version of Mirada XD3 is now available fully integrated into the Sectra workflow. This delivers greatly improved levels of productivity to radiologists and other users of medical imaging who want to access the most advanced tools and products from one workstation and without having to copy large quantities of image data from one location to another.

Using XD3,Sectra users can now be offered advanced quantification of PET, CT, MRI and SPECT including SUV measurements and access to standard disease response protocols such as RECIST for CT and PERCIST for PET and PETCT. The Mirada software supports comparison of two or more PET/CTs and also allows users to fuse MRI with PET, SPECT or CT. Mirada’s XD3 application also incorporates the latest versions of Mirada’s leading deformable image registration algorithms, which allow any combination of image modalities to be registered non-rigidly allowing for corrections to be made where patient positioning is inconsistent, or patient anatomy has changed over time.

Commenting on the new product release, Hugh Bettesworth, CEO of Mirada Medical, said: “It is central to Mirada’s philosophy that we make the advanced technologies available to the widest range of clinical users. By tightly integrating our XD3 application on Sectra PACS, users of this system can experience what we believe are the leading multi-modality workflows in the world, and do so in a way that can significantly boost productivity allowing more scans to be accurately analysed and reported.”

Commenting for Sectra, Per Elmhester, Product Manager Clinical Solutions said: “Sectra strives to constantly improve the offering to our customers. With this release our customers can now fully enjoy the benefits of the Mirada XD3-package.”

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.

About XD3

Mirada’s XD3 multi-modality clinical reading application empowers radiologists and oncologists with the image analysis they need to diagnose disease and assess follow up to treatment. XD3 combines powerful registration technologies with serial review of acquisitions acquired over time. Key product features include disease specific oncology workflows and fast, accurate and reproducible image quantification, Mirada’s world class image registration engine powers multi-modal fusion and registration across time. XD3 facilitates advanced clinical decision support and may be deployed on PACS, workstation or laptop, providing the most flexible workflow integration available anywhere. Mirada Medical continues to develop superior products to suit the needs of clinicians for reviewing images in diagnosing, staging and evaluating disease progression and response to therapy. Mirada’s XD3 product provides comprehensive levels of analytical power to the clinical user. Featuring powerful disease specific oncology workflows and fast, accurate and reproducible image quantification, XD3 facilitates advanced clinical decision support. XD3 may be deployed on PACS, home workstation or laptop, providing the most productive workflow integration available anywhere.

About the Sectra Group

Sectra successfully develops and sells cutting-edge products in the expansive niche segments of medical systems and secure communication systems. The company was founded in 1978 and has its roots in Linköping University in Sweden. Today, Sectra has offices in twelve countries and operates through partners worldwide. Sales in the 2009/2010 fiscal year totaled SEK 848 million. The Sectra share is quoted on the NASDAQ OMX Stockholm AB exchange. For more information, visit www.sectra.com.

About Sectra’s medical operations

Sectra develops and sells IT-systems and products for radiology, mammography and orthopedics. More than 1,100 hospitals, clinics and imaging centers worldwide use the systems daily, together performing over 52 million radiology examinations annually. This makes Sectra one of the world-leading companies within systems for handling digital radiology images. In Scandinavia, Sectra is the market leader with more than 50% of all film-free installations. Sectra’s systems have been installed in North America, Scandinavia and most major countries in Europe and the Far East.

http://hugin.info/143183/R/1448965/391019.pdf

METHUEN, MA–(Marketwire – October 5, 2010) – A ribbon cutting event is occurring at Suntron Corporation’s new manufacturing facility. Join Ed Wheeler, CEO of Suntron; Lt. Governor Timothy P. Murray; Congresswomen Niki Tsongas; Mayor Manzi III and Jose Bevilacqua in the opening event at 1pm, facility tour to follow.

Date:         October 5, 2010        
                                     
Time:         1:00 p.m.              
                                     
Location:     Suntron Corporation    
              300 Griffin Brook Drive
              Methuen, MA 01844